Nanotechnology Now

Our NanoNews Digest Sponsors



Heifer International

Wikipedia Affiliate Button


android tablet pc

Home > Press > Detecting the Undetectable in Prostate Cancer Testing

Abstract:
A team of Northwestern University researchers, using an extremely sensitive nanotechnology-based tool known as the biobarcode system, has detected previously undetectable levels of prostate-specific antigen (PSA) in patients who have undergone radical prostatectomy. This new assay, just one of many being developed by investigators at the Nanomaterials for Cancer Diagnostics and Therapeutics Center for Cancer Nanotechnology Excellence (Northwestern CCNE), is 300 times more sensitive than commercially available PSA tests.

Detecting the Undetectable in Prostate Cancer Testing

Bethesda, MD | Posted on November 18th, 2009

The ability to easily and quickly detect very low levels of PSA may enable doctors to diagnose men with prostate cancer recurrence years earlier than is currently possible. Prostate cancer is the second leading cause of cancer death for men in the United States. (Only lung cancer is more deadly.) "We have defined a new zero for PSA," said Chad Mirkin, Ph.D., principal investigator of the Northwestern CCNE. "This level of sensitivity in detecting low concentrations of PSA will take the blinders off the medical community, especially when it comes to tracking residual disease." This study, which was led by Mirkin and C. Shad Thaxton, M.D., appears in the Proceedings of the National Academy of Sciences (PNAS).

"This new PSA assay may alter the management of patients who have been treated with surgery for prostate cancer," said William J. Catalona, M.D., director of the Clinical Prostate Cancer Program at Northwestern's Lurie Cancer Center. He was the first to demonstrate that the PSA test, a simple blood test, could be used as a screening tool for prostate cancer. "Studies have shown that postoperative radiation therapy given early to patients with adverse pathology, called adjuvant radiation, reduces the recurrence rate and improves survival," Catalona said. After the removal of the prostate gland, patients typically have PSA levels that are undetectable when measured using conventional diagnostic tools. "Because the 'nano-PSA assay' is more sensitive than the current commercially available PSA tests, it may allow physicians to target adjuvant radiation for patients destined to have a life-threatening tumor recurrence."

The study is an early indicator of how nanotechnology can be used to improve medical diagnostics and early cancer detection. In the case of prostate cancer recurrence following primary surgical treatment, patients with detectable but non-rising PSA levels could be reassured that their cancer will not recur. This reassurance potentially could be delivered much earlier than with conventional diagnostic tools. For patients with increasing levels of PSA, detected before conventional tools are able, doctors could diagnose a recurrence and intervene accordingly.

Furthermore, the effectiveness of post-operative treatment could be assessed by monitoring a patient's PSA levels. Tracking PSA levels early, before conventional tools are able, may allow doctors to validate treatments for recurrent cancer, such as radiation, hormone therapies and chemotherapies. The most effective will be able to keep down PSA levels.

"The first route to a new therapeutic is a good diagnostic tool, and that's what we have here," said Mirkin. "This bio-barcode assay, or a variant of it, could be a commercial tool in as little as 18 months. The technology is there. Now it's a business decision."

PSA is a protein produced by the cells of the prostate gland and found in the bloodstream. This pilot study looked at serum samples from 18 post-prostatectomy patients collected over the course of a number of years.

The researchers were able to reliably and accurately quantify PSA values at less than 0.1 nanograms per milliliter, the clinical limit of detection for commercial assays. The lower limit of detection for PSA using the bio-barcode assay is approximately 300 times lower than the lower limit of detection for commercial tests. The PSA measurements were used to classify the patients as either having no evidence of disease or having a relapse of disease. The Northwestern team is now conducting a similar retrospective study of 260 patients and eventually plans to do a large prospective study.

The ultra-sensitive technology is based on gold nanoparticle probes decorated with DNA and antibodies that can recognize and bind to PSA when present at extremely low levels in a blood sample. A magnetic microparticle, outfitted with a second antibody for PSA, also is used in the assay. When in solution, the antibody-functionalized particles "recognize" and bind to PSA, sandwiching the protein between the two particles.

The key is that attached to each tiny gold nanoparticle are hundreds of identical strands of DNA. Mirkin calls this "bar-code DNA" because they have designed it as a label specific to the PSA target. After the "particle-protein-particle" sandwich is removed magnetically from solution, the DNA is removed from the sandwich and read using a Verigene® ID system, a nanotechnology platform designed to detect and quantify DNA. The amount of PSA present is calculated based on the amount of bar-code DNA. For each molecule of captured PSA, hundreds of DNA strands are released, which is one of the ways the PSA signal is amplified.

This work, which is detailed in a paper titled, "Nanoparticle-based bio-barcode assay redefines 'undetectable' PSA and biochemical recurrence after radical prostatectomy," was supported by the NCI Alliance for Nanotechnology in Cancer, a comprehensive initiative designed to accelerate the application of nanotechnology to the prevention, diagnosis, and treatment of cancer. Investigators from the Innsbruck Medical University in Austria also participated in this study. An abstract of this paper is available at the journal's Web site.

####

About NCI Alliance for Nanotechnology in Cancer
To help meet the goal of reducing the burden of cancer, the National Cancer Institute (NCI), part of the National Institutes of Health, is engaged in efforts to harness the power of nanotechnology to radically change the way we diagnose, treat and prevent cancer.

The NCI Alliance for Nanotechnology in Cancer is a comprehensive, systematized initiative encompassing the public and private sectors, designed to accelerate the application of the best capabilities of nanotechnology to cancer.

Currently, scientists are limited in their ability to turn promising molecular discoveries into benefits for cancer patients. Nanotechnology can provide the technical power and tools that will enable those developing new diagnostics, therapeutics, and preventives to keep pace with today’s explosion in knowledge.

For more information, please click here

Copyright © NCI Alliance for Nanotechnology in Cancer

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Quantum physics just got less complicated December 22nd, 2014

Enzyme Biosensor Used for Rapid Measurement of Drug December 22nd, 2014

Universality of charge order in cuprate superconductors: Charge order has been established in another class of cuprate superconductors, highlighting the importance of the phenomenon as a general property of these high-Tc materials December 22nd, 2014

Scientists reveal breakthrough in optical fiber communications December 21st, 2014

Possible Futures

A novel method for identifying the body’s ‘noisiest’ networks November 19th, 2014

Researchers discern the shapes of high-order Brownian motions November 17th, 2014

VDMA Electronics Production Equipment: Growth track for 2014 and 2015 confirmed: Business climate survey shows robust industry sector November 14th, 2014

Open Materials Development Will Be Key for HP's Success in 3D Printing: HP can make a big splash in 3D printing, but it needs to shore up technology claims and avoid the temptation of the razor/razor blade business model in order to flourish November 11th, 2014

Nanomedicine

Enzyme Biosensor Used for Rapid Measurement of Drug December 22nd, 2014

Creation of 'Rocker' protein opens way for new smart molecules in medicine, other fields December 18th, 2014

Iranian Researchers Produce Electrical Pieces Usable in Human Body December 18th, 2014

First Home-Made Edible Herbal Nanodrug Presented to Pharmacies across Iran December 17th, 2014

Sensors

Enzyme Biosensor Used for Rapid Measurement of Drug December 22nd, 2014

Promising new method for rapidly screening cancer drugs: UMass Amherst researchers invent fast, accurate new nanoparticle-based sensor system December 15th, 2014

Graphene Applied in Production of Recyclable Electrodes December 13th, 2014

Detecting gases wirelessly and cheaply: New sensor can transmit information on hazardous chemicals or food spoilage to a smartphone December 8th, 2014

Announcements

Quantum physics just got less complicated December 22nd, 2014

Enzyme Biosensor Used for Rapid Measurement of Drug December 22nd, 2014

Universality of charge order in cuprate superconductors: Charge order has been established in another class of cuprate superconductors, highlighting the importance of the phenomenon as a general property of these high-Tc materials December 22nd, 2014

Scientists reveal breakthrough in optical fiber communications December 21st, 2014

Nanobiotechnology

Scientists trace nanoparticles from plants to caterpillars: Rice University study examines how nanoparticles behave in food chain December 16th, 2014

FEI and Oregon Health & Science University Install a Complete Correlative Microscopy Workflow in Newly Built Collaborative Science Facility December 16th, 2014

UCLA engineers first to detect and measure individual DNA molecules using smartphone microscope December 15th, 2014

Biomimetic dew harvesters: Understanding how a desert beetle harvests water from dew could improve drinking water collection in dew condensers December 8th, 2014

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More










ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2014 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE